Related Projects

Throughout the course of the project we will engage with other projects that are involved in similar studies.


NEPHSTROM will carry out a first in man Phase 1b/2a clinical trial of a novel stromal cell therapy. This trial will evaluate the clinical safety and efficacy of systemic administration of allogeneic mesenchymal stromal cells (MSC), as a therapy for patients with progressive diabetic kidney disease. NEPHSTROM has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634086.

Find clinical trial information here.

Project Website:


ADIPOA-2 will design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) MCSs in the treatment of advanced osteoarthritis of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration. ADIPOA-2 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643809.

Find clinical trial information here.

Project Website:


MERLIN explores exciting new opportunities in stromal cell therapy R&D while making important contributions to the treatment of currently intractable inflammatory and immune-mediated liver diseases. MERLIN has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602363.



REDDSTAR is an EU funded project which will develop and test stromal cell therapy to treat for diabetes mellitus. The objective is to control blood glucose while also addressing a range of diabetic complications.



AUTOSTEM is developing an automated production line for stem cells. It starts with a bone marrow donation taken from the hip bone of a donor using a novel suction device being developed by the project. This is transferred in a sterile manner into a production line, where a robotic arm supports the isolation of stem cells from the bone marrow, the culturing of the stem cells in a bioreactor, and the delivery of very large numbers of these cells. AUTOSTEM has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 667932.

Project Website:


TRANSLINK is a project devoted to assessing the mid-to long-term risk factors and improve the outcome of animal (bovine/porcine)-derived Bioprosthetic Heart Valve (BHV) implants. 300,000 patients/year benefit from BHV, a major healthcare problem (second most frequent cardiac surgery).

Project Website:


The main objective of the European project Immodgel is to find innovative solutions to the frequent adverse immune reactions following implantation procedures. For this purpose, the consortium will create a personalised, immunomodulatory system that will be adjustable for any implant, medical device or transplant.

Project Website: immodgel


The overall aim of this project is to clarify the mechanisms and identify nature´s own specific control points of regulation in these adverse reactions in order to be able to significantly improve the quality of hemodialysis devices and kidney grafts by applying these concepts of regulation in hemodialysis and kidney transplantation.

Project Website:


Nano Engineering for Cross Tolerance: new approach for bioengineered, vascularised, chimeric islet transplantation in non-immunosuppressed hosts.

Project Link: NEXT CORDIS Record


The aim of the HypOrth-project (hypoallergenic implant material in Orthopaedics) is the development of personalized implants that will last the patients whole life. Testing of the patients’ genes and immune system prior to the operation will allow the selection of the right implant materials thus avoiding adverse immunological reactions. During the project, gene tests and immunological biomarkers will be discovered, and hypo-allergenic materials and antimicrobial implant surfaces will be developed.

Project Link: HypOrth

Arrest Blindness

Who are we? ARREST BLINDNESS is a consortium performing a four-year research project funded by the HORIZON 2020 program of the European Commission.

Project Link: Arrest Blindness


RESPINE will develop a rigorously proven, effective treatment of degenerative disc disease (DDD). Via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, RESPINE will assess the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. The consortium aims to provide new knowledge on immune response & safety associated with allogeneic BM-MSC intradiscal injection. This simple procedure will be cost-effective, and minimally invasive.

Project Link: RESPINE


The SCIENCE project will conduct a multicentre, double-blind placebo-controlled trial with allogeneic adipose-derived stromal cells (CSCC_ASCs) to improve myocardial function in patients with ischemic heart disease and heart failure. In addition, SCIENCE will establish a manufacturing facility for centralised production of allogeneic CSCC_ASCs, and financial health care data to demonstrate the impact of implementing treatment with the proposed new CSCC_ASC product. The project will evaluate advanced existing and new imaging techniques in order to more precisely guide the delivery of stem cells.

Project Link: SCIENCE



  1. Builds a large, inclusive EU network of ophthalmologists, scientists, trainees, aniridia patient organizations, industry, and special interest groups to create linkages and a rich training ground for a new generation of trainees;
  2. Improves aniridia management through evidence-based research, harmonized clinical protocols, pooling/sharing of samples and models, and consensus activities; and
  3. Stimulates development of novel diagnostics and treatments for aniridia based on innovative research in regenerative medicine/stem cells, investigational drugs, gene therapy, tissue engineering, transplantation, etc.

Project website: Aniridia-NET